o6-benzylguanine
Small moleculeexperimental
O6-Benzylguanine (O6-BG) is a synthetic derivative of guanine. It is an antineoplastic agent. It exerts its effect by acting as a suicide inhibitor of the enzyme O6-alkylguanine-DNA alkyltransferase which leads to interruption of DNA repair. O6-BG was used clinically in combination with the alkylating agent temozolomide for glioblastoma, however the combination was found to be overly toxic without adding significant benefit. — Wikipedia
Clinical trial activity
34 trials · 19 clinical orgs · 0 marketing orgs
Phase 1
19
Phase 2
15
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 1996 (NCT00002604)
Timeline
Indications
Studied for
- Astrocytoma · Phase 2
- Brain Neoplasms · Phase 3
- Choroid Plexus Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 2
- Craniopharyngioma · Phase 1
- DNA Mismatch Repair · Phase 1
- Ependymoma · Phase 1
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Gliosarcoma · Phase 2
- HIV · Phase 1
- Hodgkin Disease · Phase 1
- Kidney Neoplasms · Phase 1
- Liver Neoplasms · Phase 1
- Lymphoma · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Medulloblastoma · Phase 1
- Melanoma · Phase 2
- Meningioma · Phase 1
- Multiple Myeloma · Phase 2
- Neoplasms · Phase 1
- Neoplasms, Germ Cell and Embryonal · Phase 1
- Neuroblastoma · Phase 1
- Neuroectodermal Tumors · Phase 1
- Oligodendroglioma · Phase 2
- Ovarian Neoplasms · Phase 1
- Sarcoma · Phase 2
- Sezary Syndrome · Phase 1/Phase 2
Mechanism of action
- AngiotensinogenINHIBITOR
AGT inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaO6-Benzylguanine ↗
Also known as
- 6-o-benzylguanine
- 6-o-benzylguanine
- 6-o-benzylguanine
- benzylguanine
- benzylguanine
- o(6)-benzylguanine
- o6-benzylguanine
- o6-benzylguanine
- o6-benzylguanine
- o6-benzylguanine
- o(6)-bgua
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05052957 | Phase 2 | Oct 15, 2021 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT02343666 | Phase 1 | Aug 15, 2016 | National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), University of Washington |
| NCT01769911 | N/A | Feb 1, 2015 | National Cancer Institute (NCI), University of Washington |
| NCT01269424 | Phase 1 | Dec 1, 2010 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT00961220 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2010 | Case Western Reserve University, National Cancer Institute (NCI) |
| NCT00669669 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2009 | National Cancer Institute (NCI), University of Washington |
| NCT00436436 | Phase 2 | Nov 13, 2006 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00389090 | Phase 2 | Oct 1, 2006 | AOI Pharmaceuticals, Inc., Duke University |
| NCT00275002 | Phase 2 | Feb 1, 2006 | National Cancer Institute (NCI) |
| NCT00272870 | Phase 1 | Dec 1, 2005 | University of Cincinnati |
| NCT00253487 | N/A | Aug 1, 2005 | National Cancer Institute (NCI), University of Cincinnati |
| NCT00612989 | Phase 1 | Feb 1, 2005 | Duke University, Keryx, Schering-Plough |
| NCT00086970 | Phase 1 | Jun 1, 2004 | National Cancer Institute (NCI), University of Chicago |
| NCT00362921 | Phase 2 | Apr 1, 2004 | Duke University, National Cancer Institute (NCI) |
| NCT00045721 | Phase 1 | Mar 1, 2003 | National Cancer Institute (NCI), Pediatric Brain Tumor Consortium, University of Pittsburgh |
| NCT00046878 | Phase 2 | Oct 3, 2002 | Duke University, National Cancer Institute (NCI) |
| NCT00613093 | Phase 2 | Oct 1, 2002 | Duke University, Keryx, National Institutes of Health (NIH) |
| NCT00052780 | Phase 1 | Oct 1, 2002 | National Cancer Institute (NCI), Pediatric Brain Tumor Consortium |
| NCT00017147 | Phase 3 | Sep 1, 2001 | Celilo Cancer Center at Mid-Columbia Medical Center, National Cancer Institute (NCI), Southwest Oncology Group, University of Utah, University of Washington |
| NCT00006474 | Phase 1 | Mar 1, 2001 | Duke University, National Cancer Institute (NCI) |
Showing 20 of 34 trials
Page 1 / 2
Organizations
Research & Development (19)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 30 | 11 | 4 | 1996 |
| Case Western Reserve University | Academic/Hospital | 8 | 6 | 2 | 1996 |
| Duke University | Academic/Hospital | 8 | 7 | 2 | 1998 |
| University of Chicago | Academic/Hospital | 4 | 2 | 2 | 1999 |
| University of Washington | Academic/Hospital | 4 | 3 | 4 | 2001 |
| Keryx | For profit | 2 | 0 | 2 | 2002 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2002 |
| Pediatric Brain Tumor Consortium | Academic/Hospital | 2 | 1 | 1 | 2002 |
| University of Cincinnati | Academic/Hospital | 2 | 2 | 2 | 2005 |
| AOI Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2006 |
| Celilo Cancer Center at Mid-Columbia Medical Center | Academic/Hospital | 1 | 0 | 1 | 2001 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2000 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2016 |
| Schering-Plough | For profit | 1 | 0 | 1 | 2005 |
| Southwest Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2001 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 1997 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Utah | Academic/Hospital | 1 | 0 | 1 | 2001 |
| University of Vermont | Academic/Hospital | 1 | 0 | 1 | 1999 |
19 organizations
Page 1 / 1